International Clinical Trial: Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830004) titled 'Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: University Hospital, Grenoble

Condition: Myelodysplasia

Intervention: Drug: Luspatercept

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: November 2026

Target Sample Size: 150

To know more, visit https://clinicaltrials.gov/study/NCT07830004

Published by HT Digital ...